These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 2237825)

  • 21. Nifedipine reduces thromboxane A2 production by platelets without changing aggregation in hypertensive pregnancy.
    Manninen A
    Pharmacol Toxicol; 1996 Jun; 78(6):387-91. PubMed ID: 8829198
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of the calcium-entry blocking agent nifedipine on activation of human platelets and comparison with verapamil.
    Han P; Boatwright C; Ardlie NG
    Thromb Haemost; 1983 Aug; 50(2):513-7. PubMed ID: 6314581
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Verapamil is a potent inhibitor of 5-HT-induced platelet aggregation.
    Glusa E; Bevan J; Heptinstall S
    Thromb Res; 1989 Jul; 55(2):239-245. PubMed ID: 2528843
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of some calcium antagonists on aggregation by adrenalin and serotonin and on alpha-adrenoceptor radioligand binding in human platelets.
    Vinge E; Andersson TL; Larsson B
    Acta Physiol Scand; 1988 Jul; 133(3):407-16. PubMed ID: 2906509
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of calcium and calcium antagonists on [3H]-Paf-acether binding to washed human platelets.
    Wade PJ; Lunt DO; Lad N; Tuffin DP; McCullagh KG
    Thromb Res; 1986 Jan; 41(2):251-62. PubMed ID: 3961730
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of verapamil and diltiazem on aggregatory responses in cat and rabbit platelet rich plasma.
    Lippton HL; Horwitz PM; McNamara DB; Landry AZ; Kadowitz PJ
    Prostaglandins Leukot Med; 1984 Oct; 16(1):121-30. PubMed ID: 6440150
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Arachidonic acid-induced platelet aggregation and thromboxane A2 generation in patients with coronary heart disease.
    Szczeklik A; Gryglewski RJ; Musiał J; Grodzínska L; Serwónska M; Wójcik-Switek L; Marcinkiewicz E
    Acta Biol Med Ger; 1978; 37(5-6):741-2. PubMed ID: 742286
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of vitamin E supplementation on platelet thromboxane A2 production in type I diabetic patients. Double-blind crossover trial.
    Gisinger C; Jeremy J; Speiser P; Mikhailidis D; Dandona P; Schernthaner G
    Diabetes; 1988 Sep; 37(9):1260-4. PubMed ID: 3044891
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of calcium entry blockers on human platelet metabolism measured by microcalorimetry.
    Edvinsson L; Ikomi-Kumm J; Monti M
    Hum Toxicol; 1989 Mar; 8(2):131-3. PubMed ID: 2744775
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Calcium blocker diltiazem inhibits platelet activation and stimulates vascular prostacyclin synthesis.
    Mehta J; Mehta P; Ostrowski N
    Am J Med Sci; 1986 Jan; 291(1):20-4. PubMed ID: 3510543
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of nifedipine alone and with diltiazem or verapamil in hypertension.
    Saseen JJ; Carter BL; Brown TE; Elliott WJ; Black HR
    Hypertension; 1996 Jul; 28(1):109-14. PubMed ID: 8675249
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mouse antithrombotic assay: the effects of Ca++ channel blockers are platelet-independent.
    Molinari A; Guarneri L; Pacei E; de Marchi F; Cerletti C; de Gaetano G
    J Pharmacol Exp Ther; 1987 Feb; 240(2):623-7. PubMed ID: 3806414
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of thromboxane A2 synthesis in human platelets by coagulation factor Xa.
    Sinha AK; Rao AK; Willis J; Colman RW
    Proc Natl Acad Sci U S A; 1983 Oct; 80(19):6086-90. PubMed ID: 6577468
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dihydropyridine agonist Bay K 8644 inhibits platelet activation by competitive antagonism of thromboxane A2-prostaglandin H2 receptor.
    Johnson GJ; Dunlop PC; Leis LA; From AH
    Circ Res; 1988 Mar; 62(3):494-505. PubMed ID: 2449295
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Calcium-channel blocking agents.
    Leonard RG; Talbert RL
    Clin Pharm; 1982; 1(1):17-33. PubMed ID: 6764159
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An investigation into the effects of nifedipine and nimodipine on platelet function and vascular prostacyclin synthesis.
    Jeremy JY; Barradas MA; Mikhailidis DP; Dandona P
    Drugs Exp Clin Res; 1985; 11(9):645-51. PubMed ID: 3939725
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of calcium channel blockers on in vitro platelet function in whole blood using single platelet counting.
    Walley TJ; Woods KL; Barnett DB
    Thromb Haemost; 1989 Feb; 61(1):137-9. PubMed ID: 2749586
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effects of nisoldipine, diltiazem, nifedipine, and verapamil on hemodynamic parameters and red blood cells-platelet interactions in patients with arterial hypertension.
    Belousov Y; Kushnaryov V
    J Cardiovasc Pharmacol; 1991; 18 Suppl 9():S32-5. PubMed ID: 1725540
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of meloxicam on platelet function in healthy adults: a randomized, double-blind, placebo-controlled trial.
    Rinder HM; Tracey JB; Souhrada M; Wang C; Gagnier RP; Wood CC
    J Clin Pharmacol; 2002 Aug; 42(8):881-6. PubMed ID: 12162470
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Failure of calcium channel blockade to reduce platelet-mediated cyclic flow variations in dogs with coronary stenosis and endothelial injury.
    Beaughard M; Brasset M; John G; Massingham R
    J Cardiovasc Pharmacol; 1995 Oct; 26(4):577-83. PubMed ID: 8569218
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.